| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $781.7K | 0.00% | 4.50K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Kevin Hern OK01 | 2 | −$207.5K | Trimmed Aug 14, 26 | |
| Julia Letlow LA05 | 1 | −$8.0K | Sold Feb 12, 26 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 14, 26 | Kevin Hern OK01 | Joint | Sell (part) | $15,001 - $50,000 | Sep 1, 26 (18d) | |
| Mar 5, 26 | Kevin Hern OK01 | Joint | Sell | $100,001 - $250,000 | Apr 3, 26 (29d) | |
| Feb 12, 26 | Julia Letlow LA05 | Self | Sell | $1,001 - $15,000 | Mar 12, 26 (28d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Clerkin NigelChief Financial Officer | Sale at price 162.72 - 165.51 per share. | 2.3K | $372.44K |
| Aug 10, 2026 | Grais Linda Sue M.D.Director | Sale at price 162.72 - 165.51 per share. | 841 | $138.17K |
| Aug 10, 2026 | Climax John Ph.D.Director | Sale at price 162.72 - 165.51 per share. | 841 | $138.17K |
| Aug 10, 2026 | Murray CiaranDirector | Sale at price 162.72 - 165.51 per share. | 2.7K | $439.80K |
| Aug 10, 2026 | Whitaker Anne ClemDirector | Sale at price 162.72 - 165.51 per share. | 841 | $138.17K |
| Aug 10, 2026 | O'Neill Julie AnnDirector | Sale at price 162.72 - 165.51 per share. | 915 | $150.33K |
| Aug 10, 2026 | Murphy Ronan MartinDirector | Sale at price 162.72 - 165.51 per share. | 841 | $138.17K |
| Aug 10, 2026 | Mccague Eugene PacelliDirector | Sale at price 162.72 - 165.51 per share. | 841 | $138.17K |
| Aug 9, 2026 | Clerkin NigelChief Financial Officer | — | 4.3K | — |
| Aug 9, 2026 | Grais Linda Sue M.D.Director | — | 1.7K | — |
| Aug 9, 2026 | Climax John Ph.D.Director | — | 1.7K | — |
| Aug 9, 2026 | Murray CiaranDirector | — | 2.7K | — |
| Aug 9, 2026 | Whitaker Anne ClemDirector | — | 1.7K | — |
| Aug 9, 2026 | O'Neill Julie AnnDirector | — | 1.7K | — |
| Aug 9, 2026 | Murphy Ronan MartinDirector | — | 1.7K | — |
| Aug 9, 2026 | Mccague Eugene PacelliDirector | — | 1.7K | — |
| Aug 9, 2026 | Balfe Barry EdwardChief Executive Officer | Sale at price 163.80 - 165.14 per share. | 382 | $62.68K |
| Aug 6, 2026 | Balfe Barry EdwardChief Executive Officer | — | 728 | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.1 | -40.0 | 2.3 | 6.9 | 15.0 | 27.7 | -5.8 | 0.9 | 3.0 | -3.2 | −9.7% | ||
| 2025 | -5.1 | -4.6 | -7.9 | -13.5 | -14.0 | 11.6 | 16.3 | 5.2 | -1.7 | -1.8 | 7.7 | -1.5 | −13.1% |
| 2024 | -7.8 | 22.9 | 4.8 | -11.3 | 9.0 | -3.5 | 4.8 | -1.9 | -10.8 | -22.7 | -5.3 | -0.3 | −25.9% |
| 2023 | 18.8 | -2.2 | -5.3 | -9.8 | 10.6 | 17.4 | 0.5 | 3.4 | -5.3 | -0.9 | 9.4 | 6.0 | +45.7% |
| 2022 | -14.2 | -10.4 | 2.2 | -7.0 | -1.1 | -3.2 | 11.3 | -13.0 | -12.4 | 7.7 | 8.9 | -9.8 | −37.3% |
| 2021 | 4.5 | -11.3 | 8.7 | 10.5 | 3.1 | -7.6 | 17.7 | 5.1 | 2.4 | 9.4 | -5.7 | 14.5 | +58.8% |
| 2020 | -2.1 | -7.4 | -12.9 | 18.0 | 5.0 | 0.0 | 10.1 | 0.5 | 2.5 | -5.6 | 8.1 | 0.1 | +13.2% |
| 2019 | 8.3 | 0.1 | -2.4 | 0.0 | 3.6 | 8.8 | 1.4 | -1.3 | -4.4 | -0.3 | 11.1 | 5.6 | +33.3% |
| 2018 | -2.3 | 3.5 | 4.3 | -0.4 | 9.6 | 2.8 | 5.0 | 7.1 | 3.2 | -10.2 | 4.8 | -10.7 | +15.2% |
| 2017 | 11.8 | -0.3 | -4.8 | 6.0 | 11.4 | 3.9 | 7.3 | 8.0 | 0.4 | 4.4 | -1.7 | -4.0 | +49.1% |
| 2016 | -15.0 | 7.7 | 5.5 | -10.0 | 4.2 | -0.6 | 10.9 | -1.1 | 0.8 | 3.8 | -5.8 | -0.6 | −3.2% |
| 2015 | 10.6 | 22.4 | 2.2 | -8.8 | 0.8 | 3.7 | 20.1 | -4.7 | -7.8 | -10.0 | 16.4 | 4.5 | +52.4% |
| 2014 | 3.9 | 11.5 | 1.5 | -18.5 | 9.0 | 11.5 | 10.0 | -4.4 | 15.5 | -8.1 | 5.6 | -8.2 | +26.2% |
| 2013 | 5.6 | 6.3 | 3.6 | -0.5 | 6.9 | 3.2 | 10.7 | -6.8 | 12.0 | -1.1 | -5.8 | 6.0 | +45.6% |
| 2012 | 14.1 | 8.5 | 0.2 | 4.5 | -3.2 | 4.9 | 7.1 | -5.0 | 6.3 | -3.4 | 17.2 | 0.6 | +62.2% |
| 2011 | 1.7 | -10.7 | 8.5 | 13.8 | 4.2 | -7.9 | -5.2 | -4.6 | -24.5 | 4.5 | 1.3 | 0.6 | −21.9% |
| 2010 | 14.3 | -5.2 | 12.1 | 10.5 | -4.7 | 3.9 | -18.3 | -6.8 | -1.7 | -10.5 | 3.9 | 9.0 | +0.8% |
| 2009 | 2.1 | 2.1 | -21.3 | -1.9 | 10.1 | 23.7 | 8.9 | -8.0 | 13.3 | 0.9 | -8.1 | -4.3 | +10.4% |
| 2008 | 1.3 | 5.5 | -1.8 | 11.0 | -2.1 | 7.1 | 6.4 | 1.4 | -6.1 | -33.7 | -16.5 | -7.1 | −36.3% |
| 2007 | -1.1 | 11.5 | 2.4 | 10.2 | -1.2 | -5.7 | 6.9 | -2.3 | 11.7 | 13.7 | 2.3 | 4.3 | +64.1% |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Buy / hold / sell counts